Featured Products |
 |
 |
Pernix Therapeutics Announces Agreement to License a New FDA-Approved Product to Treat Gastroenterology Disease
Posted on 01/23/2012
Expansion into Gastroenterology Broadens Product Portfolio New Specialty Sales Force to be Established and Product Launch Expected in Mid-Year of 2012 THE WOODLANDS, Texas, January 23, 2012 – Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced it has entered into a license and supply agreement with a private company for [...]
Pernix Therapeutics Expands Senior Management Team to Support Continued Business Growth
Posted on 12/06/2011
David Becker appointed Chief Financial Officer Charles Hrushka appointed Vice President of Sales & Marketing Leslie White appointed Director of Regulatory Affairs & Quality Assurance THE WOODLANDS, Texas–(BUSINESS WIRE)– Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric market, today announced the appointments of David Becker as Chief [...]
Pernix Therapeutics to Present at the Piper Jaffray 23rd Annual Health Care Conference
Posted on 11/21/2011
THE WOODLANDS, Texas, November 21, 2011 – Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric market, today announced that Cooper Collins, President and Chief Executive Officer, will present at the Piper Jaffray 23rd Annual Healthcare Conference on Tuesday, November 29, 2011 at 3:30 p.m. EST. The conference [...]
Pernix Therapeutics Holdings Reports Third Quarter 2011 Financial Results
Posted on 11/15/2011
Net Revenues Increased 120% to $17.1 Million from $7.8 Million in the Third Quarter of 2010 Strong Net Revenue Growth Due Primarily to the Launches of CEDAX 180 mg Formulation, Natroba, and Generic Products Adjusted EBITDA Increased 34% to $3.6 Million from $2.7 Million in the Third Quarter of 2010 THE WOODLANDS, Texas, November 15, [...]
» Continue Reading Pernix Therapeutics Holdings Reports Third Quarter 2011 Financial Results
Pernix Therapeutics Holdings to Report Third Quarter 2011 Financial Results on November 15, 2011
Posted on 11/03/2011
Management to Host a Conference Call on November 15th at 9:00 a.m. EST THE WOODLANDS, Texas, November 3, 2011 – Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric market, today announced that it will release its third quarter 2011 financial results before the U.S. stock market [...]